Every 8-K that Savara Inc. (SVRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SVRA filings page.
Savara Inc. reported that stockholders approved key corporate changes and an executive transition. They amended the 2024 Omnibus Incentive Plan to add authorization for 18,900,000 additional shares of common stock for equity awards. Stockholders also approved a charter amendment doubling authorized common shares from 300,000,000 to 600,000,000, which became effective upon filing in Delaware.
The Board appointed Robert Lutz as Chief Financial and Operating Officer effective July 15, 2026, following the health-related resignation of current Chief Financial and Administrative Officer David Lowrance. Lutz will receive a $510,000 base salary, a stock option for 70,000 shares vesting quarterly over four years, and 35,000 restricted stock units vesting after two years. Lowrance will receive severance under his employment agreement, partial vesting acceleration, and is expected to serve as a consultant at $200 per hour. Stockholders also re-elected all director nominees and approved other proposals at the annual meeting.
Savara Inc. entered into a new headquarters lease with ML7 Yardley Partners, LP for approximately 10,795 square feet of office space at 19 W. College Avenue, Suite 200, Yardley, Pennsylvania. The lease term begins on July 1, 2026 and runs through December 1, 2031, with an option to extend for an additional five years.
Savara will pay monthly base rent of about $28,337 in the first year, with annual increases of roughly 2%. Aggregate base rent over the term is approximately $1,780,900, reflecting five months of rent abatement. The company will also pay its share of operating expenses, taxes, and utilities and has provided a $28,337 security deposit.
Savara Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital and other lenders. As amended, the agreement allows the company to borrow up to an aggregate of $105 million in term loans. The amendment resets the timing and conditions for Savara to draw up to $75 million of additional term loans, which become available only if the FDA approves its MOLBREEVI product candidate for treating aPAP. It also pushes back the initial dates for certain cash and revenue financial covenants to April 1, 2027 and September 30, 2027 if Savara’s market capitalization falls below specified thresholds, and grants lenders a first‑priority security interest in the company’s intellectual property, which can revert to a negative pledge if a related purchase agreement is terminated and unrestricted cash remains at or above $50 million.
Savara Inc. has furnished an updated corporate presentation for investors. The presentation is available on the company’s Investor Relations website and has also been provided as Exhibit 99.1 to a current report. Savara states it has no duty to update or revise the presentation, although it may choose to do so through its website, future SEC reports, press releases, or other public disclosures. The information in this investor presentation is expressly treated as furnished rather than filed under securities laws and is not automatically incorporated into other SEC filings unless specifically referenced.
Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.
The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.
Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.
Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.
Savara Inc. filed a current report to share that it has updated its corporate investor presentation. The new presentation is available on the Investor Relations section of Savara’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in the presentation and in Item 7.01 of this report is being "furnished" rather than "filed," meaning it is not subject to the usual liability provisions of the Exchange Act and will not be incorporated into other SEC filings unless specifically referenced. Savara also explains that it has no duty to update the presentation, though it may do so in the future through its website, additional SEC reports, press releases, or other public disclosures.